2 results
Approved WMORecruiting
Assessing the effectiveness and safety of parecoxib compared to placebo in pain relief children undergoing scoliosis surgery
Approved WMORecruiting
To determine the immune-related progression free survival (irPFS) rate at 21 weeks and objective response rate (irORR) at 30 weeks in patients with pMMR CRC, dMMR mCRC, dMMR EC , dMMR SBC, dMMR SC treated with pembrolizumab combined with ataluren…